3 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 5 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 2, Completed 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Atirmociclib: new trials by email Literature Review of Atirmociclib trials Research Report on Atirmociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | Pfizer | 3800 | 2026-12-01 | 2026-10-22 |
| A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease Atirmociclib - Hepatic Impairment, Healthy, Hepatic Insufficiency | Phase 1 | Recruiting | Pfizer | 28 | 2026-06-29 | 2026-08-21 |
| Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer Camizestrant, Atirmociclib - Advanced Breast Cancer | Phase 2 | Recruiting | AstraZeneca | 24 | 2026-05-06 | 2026-09-29 |
| A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants PF-07220060 - Healthy Participant | Phase 1 | Completed | Pfizer | 35 | 2025-08-14 | 2026-04-20 |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer OKI-219, Fulvestrant, Trastuzumab - Advanced Cancer, Breast Cancer | Phase 1 | Active not recruiting | OnKure, Inc. | 200 | 2024-02-26 | 2026-07-06 |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer Palazestrant, Ribociclib, Alpelisib - Metastatic Breast Cancer, ER-positive Breast Cancer | Phase 1 | Active not recruiting | Olema Pharmaceuticals, Inc. | 190 | 2022-08-31 | 2026-09-15 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 1132 | 2018-03-30 | 2026-10-09 |
Breast Neoplasms (4) · Hepatic Insufficiency (1)
Pfizer (3) · AstraZeneca (1) · Hoffmann-La Roche (1) · Olema Pharmaceuticals, Inc. (1) · OnKure, Inc. (1)
United States (6) · Australia (2) · France (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Israel (1) · Italy (1) · Taiwan (1)
2017 (1), 2023 (1)